Skip to main navigation

FibroGen China
Newsroom
Contact

About Us
Focus Areas
Pipeline
Clinical Trials
Careers
- Our Culture
- Career Opportunities
Investors and Media
Investor Relations

MENU MENU

About Us
Focus Areas
Pipeline
Clinical Trials
Careers
- Our Culture
- Career Opportunities
Investors and Media
Iphone menu

FibroGen China
Newsroom
Contact

Investors and Media

Press Releases

Keyword Search

Year

November 12, 2024
FibroGen Reports Third Quarter 2024 Financial Results
November 4, 2024
FibroGen to Report Third Quarter 2024 Financial Results
September 3, 2024
FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
August 6, 2024
FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update
July 30, 2024
FibroGen to Report Second Quarter 2024 Financial Results
July 30, 2024
FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate Update
June 18, 2024
FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024
June 3, 2024
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials
June 3, 2024
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
June 3, 2024
FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference
May 23, 2024
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting
May 7, 2024
FibroGen to Participate in Upcoming Investor Conferences
May 6, 2024
FibroGen Reports First Quarter 2024 Financial Results
April 29, 2024
FibroGen to Report First Quarter 2024 Financial Results
April 24, 2024
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting
April 2, 2024
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
March 26, 2024
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
March 11, 2024
FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
February 26, 2024
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
February 26, 2024
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea
February 20, 2024
FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results
February 5, 2024
FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024
January 25, 2024
FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

Investors and Media

Investor Overview
Stock Information
Press Releases
Events & Presentations
Corporate Governance
SEC Filings
Financial Information
Shareholder Services
Investor FAQs

FibroGen Inc.

Volume:

Minimum 15 minutes delayed. Source:

Investor and Media Contact

Investors:
David DeLucia, CFA
Vice President, Corporate FP&A and Investor Relations
ir@fibrogen.com

Shareholder Tools

Print Page
RSS Feeds
E-mail Alerts

About Us

Our Company
Our Strategy
FibroGen China
Executive Team
Board of Directors
Our Partners
ESG
Medical Information
Contact Us

Focus Areas

Our Expertise
Anemia
Pancreatic Cancer
Duchenne Muscular Dystrophy
Publications

Pipeline

R&D Pipeline
Roxadustat
Pamrevlumab

Clinical Trials

Our Priorities
Roxadustat Trials
Pamrevlumab Trials

Careers

Our Culture
Career Opportunities

Investors & Media

Investor Relations

Investor Overview
Stock Information
News Releases
Events and Presentations
Corporate Governance
SEC Filings
Financial Information
Shareholder Services
Investor FAQs

Terms of Use
Privacy Notice

About Us
Focus Area
Pipeline
Clinical Trials
Investors and Media
Terms of Use
Privacy Notice

© 2024 FibroGen, Inc.
350 Bay St, Ste 100 # 6009 San Francisco, CA 94133 USA